ARM Member Profiles

OmniaBio Inc. is a contract development and manufacturing organization (CDMO) focused on cell and gene therapies from pre-clinical through to commercialization, and a subsidiary of CCRM. Benefitting from CCRM’s existing expertise, OmniaBio provides a continuum of advanced process and analytical development, and manufacturing capabilities, by enabling focused support for clients from early clinical phase to commercial supply needs. OmniaBio is built upon leadership in iPSCs, immunotherapy and LVVs. To be located at McMaster Innovation Park, approximately one hour from the U.S. border, OmniaBio’s new commercial manufacturing site will anchor a biomanufacturing centre of excellence and will open with late clinical phase and commercial capacity in 2024 in a site totalling approximately 100,000 square feet. OmniaBio is supported by the Government of Ontario, via the Invest Ontario Fund. Visit us at www.omniabio.com.